NIS2 for pharmaceutical industry

The pharmaceutical industry includes all organizations involved in the research, production, distribution, and commercialization of medicines. Since their activities directly influence public health and the supply chain for vital products, the integrity and security of IT systems in pharma are essential. The NIS2 Directive strengthens this idea by imposing strict cybersecurity requirements on entities that play a critical role in the manufacturing and distribution of medicines. Given the global impact of the industry and the interdependence between numerous suppliers, NIS2 becomes an indispensable protection instrument.

Pharmaceutical industry NIS2 compliance requirements

Institutions and companies in the health sector carry a major responsibility, taking care of patients and the safety of medical services. The NIS2 Directive has significant implications for this sector, setting strict cybersecurity requirements for operators of essential services.

Protection of Research and Production Data
Beyond sensitive information, the pharmaceutical industry stores strategic data such as manufacturing formulas, clinical trial results, and supply chain information. Under NIS2, companies must enforce strict access controls, implement strong encryption mechanisms, and ensure continuous monitoring of suspicious activity.

Ensuring Continuity of Manufacturing Processes
A cyberattack can shut down entire production lines, compromise automated equipment, or disrupt the distribution of medicines. NIS2 requires regular system testing, frequent infrastructure updates, and a clear incident recovery plan to prevent shutdowns that could affect patients, hospitals, and the market.

Supply Chain Vulnerabilities
The pharmaceutical industry relies on suppliers, laboratories, distributors, transport partners, and global collaborators. Any weakness within this extended network can compromise the entire chain, increasing the likelihood of breaches or disruptions.

Main NIS2 Challenges for pharmaceutical industry

Applying the NIS2 Directive in pharma brings several challenges—some similar to those in healthcare, others more complex due to the industry’s global scale and competitive nature.

Diversity of Systems and Industrial Equipment
Pharmaceutical companies use a mix of modern IT systems and older Operational Technology (OT). Integrating these into a unified security framework is difficult and requires significant investment.

Data Protection
Drug formulas or clinical datasets represent highly valuable information. These types of data are attractive targets, leading to a much greater exposure to risks than in many other industries.

Budget Constraints and Limited technical capabilities
While large companies have robust resources, smaller pharmaceutical organizations often face limited cybersecurity staffing, making full NIS2 compliance more challenging.

Need for Employee Training
Laboratories, quality control systems, SCADA infrastructures, and distribution platforms are interconnected. A single incident in one part of the network can impact production, storage, and even the transportation of medicines.

Employee Training
Insufficient cybersecurity training for staff can lead to human errors, which are among the most common causes of security breaches.

FAQ

Why are pharmaceutical organizations included in NIS2?

The pharmaceutical sector plays a fundamental role in public health and handles sensitive information, including clinical trial results and data related to drug production. A cyberattack could compromise medicine safety, availability, and the supply chain. NIS2 introduces rigorous security measures to prevent such risks.

What concrete measures must pharmaceutical companies adopt?

Organizations must implement advanced cyber risk management systems, strengthen the protection of strategic data, secure digital industrial processes, and establish clear incident reporting procedures. Regular audits, continuous system updates, and comprehensive training for employees involved in critical operations are also required.

How does NIS2 affect costs and operations in the pharma industry?

Complying with NIS2 requires substantial investments in infrastructure, equipment, industrial system security, and IT workforce training. Although initial costs may be high, long-term benefits include better data protection, reduced risk of cyberattacks, increased operational resilience, and stronger trust from partners and authorities.

What happens if a pharmaceutical company does not comply with NIS2?

Non-compliance can result in financial penalties, loss of certifications, reputational damage, and production interruptions. A cyber incident may lead to compromised formulas, loss of research data, and distribution delays, causing major economic losses and impacting patient access to medication.